Abstract
Abstract Background Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (...
Cite
CITATION STYLE
APA
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., … Aguirre, A. J. (2021). Acquired Resistance to KRAS G12C Inhibition in Cancer. New England Journal of Medicine, 384(25), 2382–2393. https://doi.org/10.1056/nejmoa2105281
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free